ConductScience.org, home

Paper41301604

Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae.

Keck JM and 4 others. Antibiotics (Basel), 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae. Papers, record 41301604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301604

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2025
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-11-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Keck JMJacob M
2Dare RKRyan Khttps://orcid.org/0000-0001-9540-2683
3Saccente MMichaelhttps://orcid.org/0000-0003-3595-2274
4Vyas KSKeyur S
5Thompson RNRebekah N

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140812339NDM-driven cefiderocol resistance: effect and therapeutic considerations.Lancet Infect Dis2025https://conductscience.org/library/papers/40812339PubMed
239073671Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection.Eur J Clin Microbiol Infect Dis2024https://conductscience.org/library/papers/39073671PubMed
335992985A Multi-Disciplinary Approach for the Management of Prosthetic Joint Infections: An Australian Perspective.Malays Orthop J2022https://conductscience.org/library/papers/35992985PubMed
439389071Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.Lancet Infect Dis2025https://conductscience.org/library/papers/39389071PubMed
536225496A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam.Cureus2022https://conductscience.org/library/papers/36225496PubMed
639727974Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Curr Issues Mol Biol2024https://conductscience.org/library/papers/39727974PubMed
730150464Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/30150464PubMed
827353166In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.J Antibiot (Tokyo)2016https://conductscience.org/library/papers/27353166PubMed
939617206Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations.Int J Infect Dis2025https://conductscience.org/library/papers/39617206PubMed
1039766611Characterization of Metallo β-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam/Avibactam Combination.Antibiotics (Basel)2024https://conductscience.org/library/papers/39766611PubMed
1141028326In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii.Sci Rep2025https://conductscience.org/library/papers/41028326PubMed
1236875177In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer.JAC Antimicrob Resist2023https://conductscience.org/library/papers/36875177PubMed
1339174036Clinic of Hope: bridging infectious disease and orthopaedic surgery in prosthetic joint infection management.BMJ Open Qual2024https://conductscience.org/library/papers/39174036PubMed
1440005507Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.Pathogens2025https://conductscience.org/library/papers/40005507PubMed
1534950677Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms.Front Med (Lausanne)2021https://conductscience.org/library/papers/34950677PubMed
1640859163
In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024.
BMC Microbiol2025https://conductscience.org/library/papers/40859163PubMed
1740053286
Clinical outcomes of patients hospitalized in internal medicine wards adequately treated for bloodstream infections caused by NDM-producing Klebsiella pneumoniae. Results from a real-life retrospective multi-center study in an endemic area.
Infection2025https://conductscience.org/library/papers/40053286PubMed
1840902970Prevalence, Clinical Characteristics, and Mortality Impact of Metallo-β-Lactamase-Producing Enterobacter Cloacae Complex Infections: A Retrospective Cohort Study.J Glob Antimicrob Resist2025https://conductscience.org/library/papers/40902970PubMed
1939299261Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.Lancet2024https://conductscience.org/library/papers/39299261PubMed
2040521716Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023).J Antimicrob Chemother2025https://conductscience.org/library/papers/40521716PubMed

See all 52 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42876900The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42876900PubMed
42192725Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel)2026https://conductscience.org/library/papers/42192725PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41301604

GET https://conductscience.org/api/papers/v1/41301604/references?page=2